Document:

Exhibit 10.1

  

   

  

  
    

    

    EMPLOYMENT AGREEMENT

    

    

    This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of August 15, 2021, but effective as of July 29, 2021 (the “Effective

        Date”), by and between David H. Ferdman (“Employee”) and CyrusOne Management Services LLC, a Delaware Limited Liability Company (“Employer”).

    

    

    WHEREAS, Employer and Employee wish to memorialize the terms pursuant to which Employee has served, and shall continue to serve, as Interim Chief Executive Officer of CyrusOne Inc. (“CyrusOne”) with effect from the Effective Date;

    

    

    WHEREAS, it is the intent of Employer and Employee that if Employee becomes the permanent Chief Executive Officer of CyrusOne, Employer and Employee shall work in good faith to enter into a new
      employment agreement to memorialize the terms of such employment; and

    

    

    NOW, THEREFORE, in consideration of the above and the promises and mutual obligations of the parties contained herein, and for other valuable consideration, the receipt and sufficiency of which are
      hereby acknowledged, Employer and Employee agree as follows:

    

    

    1.          Employment.  By this Agreement, Employer and Employee set forth the terms of Employer’s employment of Employee on and after the Effective Date.

    

    

    2.         Term of Agreement.  The term of this Agreement shall be the period commencing on the Effective Date and ending on the earliest to occur of (a) the date on which a permanent successor Chief Executive
      Officer of CyrusOne is appointed and assumes such position, (b) January 29, 2022 (the “Interim Period End Date”) and (c) the date on which Employee’s employment otherwise terminates in accordance with Section 9
      (the “Term”).  Notwithstanding anything in this Agreement to the contrary, the provisions of this Agreement shall survive Employee’s termination of employment hereunder to the extent necessary to enable the
      parties to enforce their respective rights hereunder.

    

    

    3.           Duties.

    

    

    (a)          Title/Reporting.  Employee shall serve, during the Term, as President & Chief Executive Officer of CyrusOne.  Employee shall report to the Board of Directors of CyrusOne (the
      “Board”).

    

    

    (b)         Affiliates.  Employee shall furnish such managerial, executive, financial, technical and other skills, advice, and assistance in operating the CyrusOne Group as may be reasonably
      requested of Employee.  As of the Effective Date, the “CyrusOne Group” means the Employer, CyrusOne LP, CyrusOne, and their respective subsidiaries.

    

    

    (c)          Duties and Responsibilities; Efforts.  During the Term, Employee shall perform such duties, consistent with the provisions of Section 3(a), as are reasonably assigned to Employee,
      including, without limitation, service as an officer for other entities in the CyrusOne Group, and shall have authority commensurate with his titled position as delegated to him by the Board and as may be changed from time to time.  In addition, if
      the Term is terminated under Section 9(d), following the end of the Term and through the Interim Period End Date, Employee shall provide such transition services as are reasonably requested by the Board or the Chief Executive Officer of CyrusOne in
      order to support a smooth transition of Employee’s duties hereunder during the Term (the “Transition Services”). Employee shall devote a sufficient portion of Employee’s time, attention, and energies to the
      business of the CyrusOne Group as is necessary to carry out his duties pursuant to the foregoing.  Throughout the Term (and through the Interim Period End Date if applicable), Employee may continue to serve as a director of Circuit of the Americas
      and Filmwerks, Inc. and as a director and Chief Executive Officer of Cybraics, Inc.; provided that any such service, individually or in the aggregate, does not present a conflict of interest with, or materially interfere with the performance
      of, his duties for Employer.

    

    

    
      
        

    

    
    

    

    (d)          Location.  Employee shall work at a location determined in his reasonable discretion, but will travel to Employer’s Dallas, Texas headquarters office when necessary to adequately
      perform Employee’s duties.  Employee shall also travel to other locations as is necessary, or as reasonably requested by Employer, to perform Employee’s duties.  During the Term, the CyrusOne Group shall reimburse all reasonable private jet and other
      travel expenses incurred in connection with performing Employee’s duties, including related to traveling to Employer’s Dallas, Texas headquarters office by private jet, provided (x) such expenses are submitted in accordance with the applicable
      policies of the CyrusOne Group and (y) any reimbursement for private jet travel expenses shall be limited to the cost that Employee would have incurred in purchasing a refundable first class commercial airline ticket for the same route on the same
      day.

    

    

    4.          Compensation.

    

    

    (a)          Base Salary.  Employee shall receive an annual base salary (the “Base Salary”) of eight hundred and fifty thousand dollars ($850,000) per
      year, payable in accordance with Employer’s regular payroll practices as then in effect, for each year during the Term, subject to proration for any partial year, including for 2021 based on the Effective Date.

    

    

     (b)         Bonus.  In addition to the Base Salary, during the Term, Employee shall be eligible to receive a bonus (the “Bonus”).  Employee’s target
      opportunity level for the Bonus shall be equal to one million dollars ($1,000,000) and his maximum Bonus opportunity shall be equal to two million dollars ($2,000,000).  The actual Bonus earned by Employee shall be based on (i) the achievement of the
      CyrusOne financial performance objectives previously approved by the compensation committee (the “Compensation Committee”) for executive officers of the CyrusOne Group for calendar year 2021 bonuses and (ii)
      Employee successfully supporting the search process for, and the transition to, a permanent Chief Executive Officer of CyrusOne, each as determined by the Compensation Committee, with the allocation between financial and individual performance goals
      being the same as approved by the Compensation Committee for other executive officers of the CyrusOne Group.  The Bonus shall be paid no later than March 15, 2022 and, except as set forth in this Agreement, shall be subject to Employee’s continued
      employment through January 29, 2022.

    

    

    (c)          Long-Term Incentive Award.  Within 10 days following the entry of Employee and Employer into this agreement, Employee will be granted a restricted stock award with respect to
      33,459 shares of CyrusOne common stock, which is determined by dividing two million and four hundred thousand dollars ($2,400,000) by $71.73 and rounded up to the nearest whole share, (the “Sign-On Award”) that
      will vest 5/6 on December 29, 2021 and 1/6 on January 29, 2022, in each case, subject to Employee’s continued employment through the applicable date, or earlier as provided in Section 9.  The Sign-On Award will be subject to the terms and conditions
      of the applicable award agreement and the 2012 Long Term Incentive Plan, as amended from time to time, or other applicable plan (as applicable to the Sign-On Award or other future equity grants, the “Equity Plan”),

      except as otherwise provided in this Agreement.  If the Term continues for longer than six (6) months, Employer shall consider in good faith whether any additional equity grants would be appropriate or necessary to adequately compensate Employee.

    

    

    
      - 2 -

      
        

    

    

    

    (d)          Board Compensation.  Employee acknowledges and agrees that, during the Term, he shall not receive any additional compensation, including any cash retainers or equity grants, in
      respect of his service on the Board; provided that, any equity awards granted in respect of such service prior to the Effective Date shall continue to vest in accordance with their terms.  Immediately following the termination of the Term for
      any reason, Employee’s Board compensation (including both cash and equity components) shall be reinstated in accordance with CyrusOne’s non-employee director compensation policies.

    

    

    (e)          Legal Fees.  Subject to Employee providing reasonable documentation, Employer shall pay, or reimburse, Employee’s reasonable legal fees incurred in connection with the negotiation
      and entry into this Agreement and the award agreement with respect to the Sign-On Award and any related securities and tax filings, with the aggregate amount of such reimbursements not to exceed $10,000.

    

    

    (f)          Employer and Employee both acknowledge and agree that this Agreement and the foregoing compensation, including the Sign-On Award, is not being provided as a result of, in connection
      with, and is not contingent on, a pending or contemplated transaction to which Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”) would apply, and that this Agreement and the foregoing compensation were the result of
      arm’s length negotiations with the intent of, among other things, providing Employee with appropriate compensation for the services to be provided pursuant to Section 3.

    

    

    5.           Business Expenses.  All reasonable and necessary expenses incurred by Employee in the course of the performance of Employee’s duties to the CyrusOne Group shall be reimbursable in accordance with
      Employer’s then current travel and expense policies.

    

    

    6.           Confidentiality and Return of Company Property.  Employee hereby acknowledges and agrees that he has an obligation to maintain the confidentiality of all confidential, proprietary or trade secret
      information of the CyrusOne Group, during and following the termination of the Term, and to only use such information for the benefit of the CyrusOne Group.  Upon the termination of the Term for any reason, Employee agrees to return any and all
      property of the CyrusOne Group and delete any confidential, proprietary or trade secret information of the CyrusOne Group from any of Employee’s personal devices (other than any such information that is related to Employee’s continued service to the
      CyrusOne Group, including as a member of the Board, following the termination of the Term).

    

    

    
      - 3 -

      
        

    

    

    

    7.          Benefits.

    

    

    (a)          While Employee remains in the employ of Employer, Employee shall be eligible to participate in all of the various employee benefit plans and programs which are made available to
      similarly situated officers of CyrusOne, in accordance with the eligibility provisions and other terms and conditions of such plans and programs.

    

    

    (b)          Notwithstanding anything contained herein to the contrary, the Base Salary and any Bonuses otherwise payable to Employee shall be reduced by any benefits paid to Employee under any
      disability plans made available to Employee by the CyrusOne Group (the “Disability Plans”) in accordance with the terms of such Disability Plans.

    

    

    8.          Remedies.

    

    

    (a)           The parties hereto agree to submit to final and binding arbitration any dispute, claim or controversy, relating to Employee’s employment with or termination from the CyrusOne Group,
      whether for breach of this Agreement or violation of any of Employee’s statutory or common law rights (herein, a “claim”).  The parties further agree that the arbitrability of any dispute between them,
      including whether or to what extent the provisions of this Section 8 are unconscionable or otherwise unenforceable, is a decision that will be submitted exclusively to the arbitrator, and will not be decided by any Federal or state court.

    

    

    (b)           This agreement to arbitrate and any resulting arbitration award are enforceable under and subject to the Federal Arbitration Act, 9 U.S.C. § 1 et seq. (the “FAA”).  If the FAA is held not to apply for any reason, then the laws of the State of Texas concerning the enforceability of arbitration agreements and awards (without regard to its conflicts of laws principles)
      shall govern this agreement to arbitrate and the arbitration award.

    

    

    (c)            All of a party’s claims must be presented at a single arbitration hearing.  Any claim not raised at the arbitration hearing is waived and released.  The arbitration hearing shall take
      place in Dallas, Texas.

    

    

    (d)          The arbitration process shall be governed by the Employment Arbitration Rules and Mediation Procedures of the American Arbitration Association (“AAA”)

      except to the extent they are modified by this Agreement.  In the event that any provisions of this Section 8 are determined by AAA to be unenforceable or impermissibly contrary to AAA rules, then this Section 8 shall be modified as necessary to
      comply with AAA requirements.

     

    

    (e)           Employee has had an opportunity to review the AAA rules and the requirements that Employee must pay a filing fee, which Employer has agreed to split on an equal basis. 

    

    

    (f)         The arbitrator shall be selected from a panel of arbitrators chosen by AAA, all of whom shall be currently licensed to practice law in Texas.  After the filing of a Request for
      Arbitration, AAA shall send simultaneously to Employer and Employee an identical list of names of five persons chosen from the panel.  Each party shall have ten (10) days from the transmittal date in which to strike up to two (2) names, number the
      remaining names in order of preference, and return the list to AAA.

    

    

    
      - 4 -

      
        

    

    

    

    (g)          Any pre-hearing disputes shall be presented to the arbitrator for expeditious, final, and binding resolution.

    

    

    (h)          The award of the arbitrator shall be in writing and shall set forth each issue considered and the arbitrator’s finding of fact and conclusions of law as to each such issue.

    

    

    (i)           The remedy and relief that may be granted by the arbitrator to Employee are limited to lost wages, benefits, cease and desist and affirmative relief, compensatory, liquidated, and
      punitive damages and reasonable attorney’s fees, and shall not include reinstatement or promotion.  If the arbitrator would have awarded reinstatement or promotion, but for the prohibition in this Agreement, the arbitrator may award reasonable front
      pay.  The arbitrator may assess to either party, or split, the arbitrator’s fee and expenses and the cost of the transcript, if any, in accordance with the arbitrator’s determination of the merits of each party’s position, but each party shall bear
      any cost for its witnesses and proof.

    

    

    (j)           Nothing herein shall prevent either party from taking the deposition of any witness where the sole purpose for taking the deposition is to use the deposition in lieu of the witness
      testifying at the hearing and the witness is, in good faith, unavailable to testify in person at the hearing due to poor health, residency, and employment more than fifty (50) miles from the hearing site, conflicting travel plans or other comparable
      reason.

    

    

    (k)          Employer and Employee consent that judgment upon the arbitration award may be entered in any Federal or state court that has jurisdiction.

    

    

    (l)           Except for claims excluded from arbitration under Section 8(a), neither party shall commence or pursue any litigation on any claim that is or was subject to arbitration under this
      Agreement.

    

    

    (m)        All aspects of any arbitration procedure under this Agreement, including the hearing and the record of the proceedings, are confidential and shall not be open to the public, except to the
      extent the parties agree otherwise in writing, or as may be appropriate in any subsequent proceedings between the parties, or as may otherwise be appropriate in response to a governmental agency or legal process or as may be required to be disclosed
      by the CyrusOne Group pursuant to applicable law, rule, or regulation to which the CyrusOne Group is subject, including requirements of the Securities and Exchange Commission (the “SEC”) and any stock exchanges
      on which CyrusOne’s securities are listed.

    

    

    9.          Termination.

    

    

    (a)          Termination for Terminating Disability.

    

    

     (i)          Employer or Employee may terminate the Term upon Employee’s failure or inability to perform the services required hereunder, because of any physical or mental infirmity for which
      Employee receives disability benefits under any Disability Plans, over a period of one hundred twenty (120) consecutive working days during any twelve (12) consecutive month period, or if longer, a period equal to the elimination period under any
      Disability Plan applicable to Employee (a “Terminating Disability”).

    

    

    
      - 5 -

      
        

    

    

    

     (ii)          If Employer or Employee elects to terminate the Term in the event of a Terminating Disability, such termination shall be effective immediately upon the giving of written notice by the
      terminating party to the other party.

    

    

    (iii)          Upon termination of the Term on account of a Terminating Disability, Employer shall pay Employee (1) the Accrued Obligations (all subject to offset for any amounts received pursuant to
      the Disability Plans, in accordance with the terms of such Disability Plans) and (2) an amount equal to the Bonus that Employee otherwise would have earned under Section 4(b) had no such termination of employment occurred, based on actual achievement
      of the applicable performance goals, as determined by the Compensation Committee, and prorated for the number of days Employee was employed by Employer during the year of termination compared to the number of days in the period beginning on the
      Effective Date and ending on the Interim Period End Date, payable in accordance with the timing set forth in Section 4(b) (the “Pro-Rata Bonus”).  In addition, upon termination of the Term on account of a
      Terminating Disability, a prorated portion of the Sign-On Award shall vest based on the number of days Employee was employed by Employer during the Term compared to the number of days in the period beginning on the Effective Date and ending on the
      Interim Period End Date (less any portion that has previously vested) and any other outstanding equity incentive awards shall be treated in accordance with the applicable provisions of the applicable incentive plan or related award agreements.

    

    

    (iv)          If the parties elect not to terminate the Term upon an event of a Terminating Disability and Employee returns to active employment with Employer prior to such a termination, or if such
      disability exists for less than the period of time necessary to constitute a Terminating Disability, the provisions of this Agreement shall remain in full force and effect.

    

    

    (b)          Termination on Account of Death of Employee.  The Term terminates immediately and automatically on the death of Employee; provided, however, that Employer shall
      pay Employee’s estate (1) the Accrued Obligations and (2) the Pro-Rata Bonus.  Upon termination of the Term and Employee’s employment on account of the death of Employee, a prorated portion of the Sign-On Award shall vest based on the number of days
      Employee was employed by Employer during the Term compared to the number of days in the period beginning on the Effective Date and ending on the Interim Period End Date (less any portion that has previously vested) and any other outstanding equity
      incentive awards shall be treated in accordance with the applicable provisions of the applicable incentive plan or related award agreements.

    

    

    (c)          Termination by Employer for Cause.  Employer may terminate the Term immediately, upon written notice to Employee, for Cause.  For purposes of this Agreement, Employer shall have “Cause” to terminate the Term only if the Board determines that, on or after the Effective Date with respect to events that occur on or after the Effective Date, there has been (i) fraud, misappropriation,
      embezzlement, or misconduct constituting serious criminal activity on the part of Employee or (ii) willful and material violations of material policies of the CyrusOne Group by the Employee in connection with his employment that results, or is
      reasonably likely to result, in material financial or reputational damage to the CyrusOne Group; provided, however, that, to the extent such violation under the foregoing clause (ii) is curable, Employer has given Employee written
      notice setting forth in reasonable specificity the event(s) or circumstance(s) that it believes constitutes Cause and Employee has failed to cure such event(s) or circumstance(s) within fifteen (15) days after having received such written notice from
      Employer.  Upon termination for Cause, Employer shall pay Employee only the Accrued Obligations and the Sign-On Award shall be forfeited.  Upon a termination for Cause, Employee shall immediately deliver to the Board his resignation as a member of
      the Board.

    

    

    
      - 6 -

      
        

    

    

    

    (d)          Termination of Term, Termination by Employer Other than for Cause, Death, or Disability, Termination by Employee for Good Reason.  Employer may terminate the Term immediately upon
      written notice to Employee for any reason.  In the event (x) the Term terminates in accordance with Section 2, in which case, for the avoidance of doubt, Employee’s employment shall automatically terminate (except in the case Employee is appointed
      and becomes the permanent Chief Executive Officer of CyrusOne) (y) Employer terminates the Term for any reason other than those set forth in Sections 9(a), (b) or (c) or (z) Employee terminates the Term by resigning with Good Reason (as defined
      below), the Sign-On Award shall vest in full (to the extent not previously vested) and, provided Employee provides the Transition Services, Employee shall remain eligible to continue receiving the compensation provided for in Sections 4(a) and 4(b)
      through the Interim Period End Date (without regard to any reduction that would constitute Good Reason).

    

    

    (e)          Voluntary Resignation by Employee without Good Reason.  Employee may resign without Good Reason upon sixty (60) days’ prior written notice to Employer.  In the event of a
      resignation under this Section 9(e), the Term shall terminate and Employee shall be entitled only to the Accrued Obligations and the Pro-Rata Bonus.  For the avoidance of doubt, upon such a termination, the Sign-On Award shall be forfeited.

    

    

      (f)          Good Reason Defined. “Good Reason” means, without Employee’s consent, (i)  a diminution
      in Employee’s title, duties, position or responsibilities or a requirement that Employee report to anyone other than directly to the Board, (ii) a requirement that Employee be based in any particular location (other than travel contemplated by
      Section 3(d)), (iii) any reduction in Employee’s Base Salary or Bonus opportunity or (iv) any other material breach of a material provision of this Agreement by Employer or the CyrusOne Group; provided, that none of the foregoing events shall
      constitute Good Reason unless (x) Employee provides written notice to Employer of the event that constitutes Good Reason within thirty (30) days of Employee first having actual knowledge of such event, (y) Employer fails to cure such event within
      fifteen (15) days after receipt from Employee of such written notice, and (z) Employee resigns for Good Reason within forty-five (45) days of Employee first having actual knowledge of the occurrence of such event.  In addition, Employee will not have
      Good Reason as a result of the appointment of a permanent successor Chief Executive Officer of CyrusOne and such individual assuming such position.

    

    

      (g)          Section 9 Payments and Release.  Upon termination of the Term as a result of an event of termination described in this Section 9 and except for Employer’s payment of the
      Accrued Obligations and other amounts described in this Section 9, all further compensation under this Agreement shall terminate.  Employee further agrees that as a condition precedent to Employee’s receipt of payments and benefits under this Section
      9 (other than the Accrued Obligations), upon the request of Employer and by a reasonable deadline set by Employer (to ensure that payments can be made by the dates specified in this Section 9 following the expiration of the time for revocation of the
      Release (as defined below) as permitted by law), Employee shall (i) execute a separation agreement that sets forth (A) the date of Employee’s termination and the effect of his termination under the compensation and benefit plans of the CyrusOne
      Group, (B) the compensation and benefits to be received under this Agreement and any conditions to their receipt provided for in this Agreement, (C) covenants requiring Employee to maintain the confidentiality of the CyrusOne Group’s confidential
      information and to return any property of the CyrusOne Group and (D) a release of claims in the form attached as Exhibit A hereto (subject to updates to the extent necessary to reflect changes in applicable law) (the “Release”) and (ii) execute and not revoke the Release.

    

    

    
      - 7 -

      
        

    

    

    

    (g)          Additional Terms.  To the extent provided below, the following provisions apply under this Section 9 and the other provisions of the Agreement.

    

    

     (i)          “Accrued Obligations” shall mean (A) any Base Salary accrued through the date of termination, (B) any Bonus earned but not yet paid for the year
      preceding the year in which the termination occurs, subject to certification by the Compensation Committee of any performance goals applicable to such bonus, (C) reimbursement for any business expenses properly incurred prior to the date of
      termination and (D) any nonforfeitable amounts or benefits, including continuation and conversion rights, provided under any employee plan, not including any severance, separation pay or supplemental unemployment benefit plan, in accordance with the
      terms of such plan.

    

    

     (ii)         Employee shall not be required to seek or accept other employment, or otherwise to mitigate damages, as a condition to the receipt of any payments or benefits under this Section 9, and
      the payments and benefits under this Section 9 shall not be offset by any compensation or other amounts received from any other source.

    

    

     (iii)         This Agreement and the amounts payable and other benefits hereunder are intended to comply with, or otherwise be exempt from, Section 409A of the Code (“Section 409A”).  This Agreement shall be administered, interpreted and construed in a manner consistent with Section 409A.  If any provision of this Agreement is found not to comply with, or otherwise not to be exempt from, the
      provisions of Section 409A, it shall be modified and given effect, in the sole discretion of the Board or Compensation Committee and without requiring Employee’s consent, in such manner as the Board or Compensation Committee determines to be
      necessary or appropriate to comply with, or to effectuate an exemption from, Section 409A.  Each payment under this Agreement shall be treated as a separate identified payment for purposes of Section 409A.  The preceding provisions shall not be
      construed as a guarantee by Employer of any particular tax effect to Employee of the payments and other benefits under this Agreement.

    

    

     (A)          With respect to any reimbursement of expenses of, or any provision of in-kind benefits to, Employee, as specified under this Agreement, such reimbursement of expenses or provision of
      in-kind benefits shall be subject to the following conditions:  (1) the expenses eligible for reimbursement or the amount of in-kind benefits provided in one taxable year shall not affect the expenses eligible for reimbursement or the amount of
      in-kind benefits provided in any other taxable year, except for any medical reimbursement arrangement providing for the reimbursement of expenses referred to in Section 105(b) of the Code; (2) the reimbursement of an eligible expense shall be made no
      later than the end of the year after the year in which such expense was incurred; and (3) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit.

    

    

    
      - 8 -

      
        

    

    

    

     (B)          If a payment obligation under this Agreement arises on account of Employee’s termination of employment and if such payment is “deferred compensation” (as defined under Treasury
      Regulation Section 1.409A-1(b)(1)) subject to Section 409A, the payment shall be paid only in connection with Employee’s “separation from service” (as defined in Treas. Reg. Section 1.409A-1(h)).  If a payment obligation under this Agreement arises
      on account of Employee’s “separation from service” (as defined under Treas. Reg. Section 1.409A-1(h)) while Employee is a “specified employee” (as defined under Treas. Reg. Section 1.409A-1(h) and using the identification methodology selected by
      Employer from time to time), any payment of “deferred compensation” (as defined under Treasury Regulation Section 1.409A-1(b)(1), after giving effect to the exemptions in Treasury Regulation Sections 1.409A-1(b)(3) through (b)(12)) that is scheduled
      to be paid within six months after such separation from service shall accrue without interest and shall be paid on the first day of the seventh month beginning after the date of Employee’s separation from service or, if earlier, within fifteen (15)
      days following Employee’s death.

    

    

    10.          Withholdings.  All amounts payable under this Agreement will be subject to withholdings as required by law.

    

    

    11.          Assignment.  All rights and duties of Employee arising under this Agreement, and the Agreement itself, are non-assignable by Employee.  Employer may elect to assign this Agreement, provided that
      such assignment, other than to a successor to Employer’s business that expressly adopts and agrees to be bound by this Agreement, shall not relieve Employer of its obligations under this Agreement, and Employer shall guarantee payment and performance
      of all such obligations by the assignee.

    

    

    12.          Notices.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if delivered personally or by certified mail to Employee at Employee’s place of
      residence as then recorded on the books of Employer or to Employer at its principal office.

    

    

    13.          Waiver.  No waiver or modification of this Agreement or the terms contained herein shall be valid unless in writing and duly executed by the party to be charged therewith.  The waiver by any party
      hereto of a breach of any provision of this Agreement by the other party shall not operate or be construed as a waiver of any subsequent breach by such party.

    

    

    14.          Governing Law; Venue.  This Agreement shall be governed by the laws of the State of Texas and, to the extent applicable, Federal law, and the parties agree to submit to the jurisdiction of the
      state and Federal courts sitting in Dallas, Texas counties for all disputes not covered by Section 8.

    

    

    15.          Entire Agreement.  This Agreement, together with the award agreement with respect to the Sign-On Award and the Equity Plan, contains the entire agreement of the parties with respect to Employee’s
      employment by Employer, and supersedes any and all prior agreements between or among the parties.  There are no other contracts, agreements, or understandings, whether oral or written, existing between them except as contained or referred to in this
      Agreement or evidencing equity awards granted in respect of Board service. With respect to the Sign-On Award and any other equity awards granted to Employee in connection with his employment, (a) in the event of any conflict between the terms of this
      Agreement, on the one hand, and the terms of the Equity Plan and any award agreement (including the award agreement with respect to the Sign-On Award), on the other hand, the terms of the applicable award agreement shall govern, and (b) in the event
      of any conflict between the terms of this Agreement and the terms of the Equity Plan, the terms of this Agreement shall govern (other than any purported conflict relating to terms of the Equity Plan that would require shareholder approval to amend,
      in which case, the terms of the Equity Plan shall govern).

    

    

    
      - 9 -

      
        

    

    

    

    16.          Severability.  In case one or more of the provisions of this Agreement is held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality or other enforceability shall not
      affect any other provisions hereof, and this Agreement shall be construed as if such invalid, illegal or unenforceable provisions have never been contained herein.

    

    

    17.          Successors and Assigns.  Subject to the requirements of Section 11 above, this Agreement shall be binding upon Employee, Employer and Employer’s successors and assigns.

    

    

    18.          Non-Disparagement.  At all times during the Term and thereafter, regardless of the reason for termination, Employee will not disparage the CyrusOne Group in any way which could adversely affect the
      goodwill, reputation, and business relationships of the CyrusOne Group with the public generally, or with any of their customers, suppliers, or employees, and Employer and the current members of the Board and the current senior executive officers of
      CyrusOne (the “Covered Individuals”) shall not make public statements in their respective official capacities that disparage Employee in any way which could adversely affect the reputation and business
      relationships of Employee with the public generally, or with any of his future employers. This Section 18 and any other non-disparagement covenant entered into by Employee and any member of the CyrusOne Group will not be violated by (i) truthful
      statements made in response to disparaging statements made by the other party about, as applicable, Employee, the CyrusOne Group or the applicable Covered Individual; (ii) truthful statements required to be made by law or legal process; (iii)
      truthful statements made in any dispute involving Employee and any member of the CyrusOne Group or the applicable Covered Individual, where such statements are relevant to such dispute; or (iv) non-public statements made in the ordinary course of
      performing services to the CyrusOne Group that Employee or the applicable Covered Individual, as applicable, reasonably believes to be in the best interests of the CyrusOne Group.

    

    

    19.          Protected Rights.

    

    

      (a)          Notwithstanding any other provision of this Agreement, nothing contained in this Agreement limits Employee’s ability to file a charge or complaint with the Equal Employment
      Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health Administration, the SEC or any other federal, state or local governmental agency or commission (collectively, “Government
        Agencies”), or from providing truthful testimony in response to a lawfully issued subpoena or court order.  Employee understands that this Agreement does not limit his ability to communicate with any Government Agencies or otherwise
      participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to Employer.  In addition, Employee shall not be prohibited from providing any
      confidential information to the SEC, cooperating with or assisting in an SEC investigation or proceeding or receiving any monetary award as set forth in Section 21F of the Securities Exchange Act of 1934 or otherwise for information provided to the
      SEC.

    

    

    
      - 10 -

      
        

    

    

    

      (b)          The federal Defend Trade Secrets Act of 2016 (the “Act”) provides immunity from liability in certain circumstances to Employer’s employees,
      contractors, and consultants for limited disclosures of Employer “trade secrets,” as defined by the Act. Specifically, Employer’s employees, contractors, and consultants may disclose trade secrets: (i) in confidence, either directly or indirectly, to
      a Federal, state, or local government official, or to an attorney, “solely for the purpose of reporting or investigating a suspected violation of law,” or (ii) “in a complaint or other document filed in a lawsuit or other proceeding, if such filing
      is made under seal.” Additionally, employees, contractors, and consultants who file lawsuits for retaliation by an employer for reporting a suspected violation of law may use and disclose related trade secrets in the following manner:  (A) the
      individual may disclose the trade secret to his/her attorney, and (B) the individual may use the information in the court proceeding, as long as the individual files any document containing the trade secret under seal and does not otherwise disclose
      the trade secret “except pursuant to court order.”

    

    

    20.         Counterparts.  This Agreement may be executed in several counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument. Signatures delivered
      by facsimile or electronic means (including by “pdf”) shall be deemed effective for all purposes.

    

    

    

    

    [Signature page follows]

    

    

    
      - 11 -

      
        

    

    
    

    

              IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the day and year first above written.

    

    

    

    

    
      	 	CYRUSONE MANAGEMENT SERVICES LLC,

            	 
	 	 	 	 
	

            	
              by 

            	/s/ Robert M. Jackson

            	 
	 	 	Name:	Robert M. Jackson

            	 
	 	 	Title:	
              Executive Vice President, General Counsel and Secretary

            	 
	 	 	 	 
	 	 	  

            	 
	 	Date:  August 13, 2021  

            	 

    

    

    

    

    

    
      

      

      
        	 	EMPLOYEE,

              	 
	 	 	 	 
	

              	
                by 

              	/s/ David H. Ferdman

              	 
	 	 	Name:	David H. Ferdman

              	 
	 	 	 	 
	 	 	 	 
	 	Date:  August 15, 2021  

              	 

      

      

      

      

      

    

    
      - 12 -

      
        

    

    

    

    Exhibit A

    

    

    This Release Agreement (this “Release”) is made by and among David H. Ferdman (“Employee”) and CyrusOne Management Services LLC (“Employer”) as of the date set forth below in connection with the Transition and Separation Agreement dated _______, 202[2] (the “Separation Agreement”) between Employee and
      Employer and in association with Employee’s separation of employment from the CyrusOne Group (as defined in the Separation Agreement).  In consideration of the compensation and benefits to be paid in accordance with Section 9(d) of the Employment
      Agreement between Employer and Employee dated as of August 15, 2021 (the “Employment Agreement”) and which are described in the Separation Agreement (the “Separation Pay and
        Benefits”), which shall only be paid or provided to Employee if he executes this Release on or following the Termination Date (as defined in the Separation Agreement), and this Release becomes effective and irrevocable within sixty (60) days
      following the Termination Date, Employee hereby agrees to the following:

    

    

    	1.	
            General Release.

          

    

    

    	

          	A.	
            Employee unconditionally, irrevocably and absolutely releases and discharges Employer, and any and all parent and subsidiary corporations, divisions and affiliated corporations, partnerships or other affiliated entities of Employer, past
              and present, as well as Employer’s past and present employees, officers, directors, partners, members, insurers, employee benefit plans and fiduciaries, attorneys, agents, successors and assigns (collectively, “Released Parties”), from all claims related in any way to the transactions or occurrences between them prior to or at the Termination Date, to the fullest extent permitted by law, including, but not limited to, Employee’s
              employment with Employer, Employee’s termination of employment, and all other losses, liabilities, claims, charges, demands and causes of action, known or unknown, suspected or unsuspected, arising directly or indirectly out of or in any way
              connected with Employee’s employment with Employer that may be released under applicable law (the “Released Claims”).  This release is intended to have the broadest possible application and includes,
              but is not limited to, any tort, contract, common law, constitutional or other statutory claims, including, but not limited to alleged violations of federal, state or local law (including, without limitation, Title VII of the Civil Rights Act
              of 1964, the Americans with Disabilities Act, the Age Discrimination in Employment Act of 1967 (the “ADEA”), the Family and Medical Leave Act, the Civil Rights Act of 1866, the Employee Retirement
              Income Security Act (with respect to unvested benefits), and Chapter 21 of the Texas Labor Code, all as amended), and all claims for attorneys’ fees, costs and expenses.  Notwithstanding the broad terms of this release, Employee is not
              releasing (i) any claim or right to director and officer (D&O) insurance coverage for any acts arising prior to the Termination Date, (ii) any claim or rights arising under the Separation Agreement, (iii) any claim or rights to earned
              compensation or vested employees benefits, including the Accrued Obligations (as defined in the Employment Agreement), (iv) any rights as an equityholder of the Company or with respect to equity or vested incentive equity awards of the
              Company; and/or (v) any claim or right arising after the date Employee signs this Release.

          

    

    

    
      
        

    

    
    

    

    

    

    	

          	B.	
            Notwithstanding the broad scope of the release set forth in this Section 1, this Release is not intended to bar, and the defined term “Released Claims” does not include, any claims that, as a matter of law, whether by statute or
              otherwise, may not be waived, such as claims for workers’ compensation benefits or unemployment insurance benefits or Employee’s right to provide information to, participate in a proceeding before, or pursue relief from the National Labor
              Relations Board, the Equal Employment Opportunity Commission, or the Securities and Exchange Commission (“SEC”), and other similar federal, state, or local government agencies (collectively, “Government Agencies”).  Provided, however, that if Employee does pursue an administrative claim that may not be waived as a matter of law, or such a claim is pursued on Employee’s behalf, Employee expressly
              waives Employee’s individual right to recovery of any type, including monetary damages or reinstatement, for any such claim, except that this limitation on monetary recovery will not apply to claims for workers’ compensation, unemployment
              insurance benefits, or any right to seek or recover a monetary whistleblower award from Government Agencies as part of a government-administered whistleblower award program for providing information directly to  Government Agencies (a “Whistleblower Award”).  In addition, Employee shall not be prohibited, pursuant to this Release or the Separation Agreement, from providing any confidential information to the SEC, cooperating with or
              assisting in an SEC investigation or proceeding or receiving any monetary award as set forth in Section 21F of the Securities Exchange Act of 1934.

          

    

    

    	

          	C.	
            Employee acknowledges that Employee may discover facts or law different from, or in addition to, the facts or law that Employee knows or believes to be true with respect to the Released Claims and agrees, nonetheless, that this Release and
              the Separation Agreement shall be and remain effective in all respects notwithstanding such different or additional facts or law or the discovery of them.

          

    

    

    	

          	D.	
            Subject to Section 1.B above, Employee declares and represents that Employee intends this Release to be complete and not subject to any claim of mistake, and that the release herein expresses a full and complete release of the Released
              Claims and Employee intends the release herein to be final and complete.  Employee executes this Release with the full knowledge that the release herein covers all Released Claims against the Released Parties, to the fullest extent permitted
              by law.

          

    

    

    	

          	E.	
            By execution of this Release, Employee represents that (a) Employee has been paid or otherwise received all wages, vacation, bonuses, or other amounts owed to Employee by Employer, other than those specifically addressed in the Separation
              Agreement as payable following the Termination Date, (b) Employee has not been denied any request for leave or accommodation to which Employee believes Employee was legally entitled, and Employee was not otherwise deprived of any of
              Employee’s rights under the Family and Medical Leave Act, the Americans with Disabilities Act, or any similar state or local statute, and (c) Employee has not suffered any harassment, retaliation, employment discrimination, or work-related
              injury or illness while employed by Employer.

          

    

    

    
      A-2

      
        

    

    
    

    

    

    

    	2.	
            Covenant Not to Sue.  Subject to Section 1.B above or as otherwise provided in this Release, Employee agrees that Employee is precluded from and is waiving all rights to sue based on the Released
              Claims or to obtain equitable, remedial or punitive relief from any or all of the Released Parties of any kind whatsoever based on the Released Claims, including, without limitation, reinstatement, back pay, front pay, attorneys’ fees and any
              form of injunctive relief.  Employee represents that, as of the date of Employee’s signing this Release, Employee has not filed any lawsuits, charges, complaints, petitions, claims or other accusatory pleadings against the Employer or any of
              the other Released Parties in any court or with any Government Agency and, to the best of Employee’s knowledge, no person or entity has filed any such lawsuits, charges, complaints, petitions, claims or other accusatory pleadings against the
              Employer or any of the other Released Parties on Employee’s behalf.  Employee further represents that Employee has not assigned, or purported to assign, Employee’s right to file any such lawsuits, charges, complaints, petitions, claims or
              other accusatory pleadings against the Employer or any of the other Released Parties to any other person or entity.  Employee agrees not to assist, or otherwise participate in, any claims, cross-claims, third-party claims, demands,
              complaints, causes of action related in any way to the allegations that were or could have been made by Employee with respect to the claims and causes of action released as part of this Release, unless required to do so by law.

          

    

    

    	3.	
            Older Workers’ Benefit Protection Act.  This Release is intended to satisfy the requirements of the Older Workers’ Benefit Protection Act, 29 U.S.C. sec. 626(f).  Employee is advised to consult with
              an attorney before executing this Release.

          

    

    

    	

          	A.	
            ADEA Release and Waiver.  By entering into this Release, Employee is giving up important rights, including, but not limited to, any rights and claims that may exist under the ADEA.

          

    

    

    	

          	B.	
            Acknowledgments.  Employee acknowledges and agrees that (a) Employee has read and understands the terms of this Release; (b) Employee has been advised in writing, by this Release, to consult with an
              attorney before executing this Release; (c) Employee has obtained and considered such legal counsel as Employee deems necessary; and (d) by signing this Release, Employee acknowledges that Employee does so freely, knowingly, and voluntarily.

          

    

    

    	

          	C.	
            Time to Consider.  Employee has at least [21][45] days beginning on the Termination Date to consider whether or not to enter into this Release and return a signed copy to Employer (although Employee
              may elect not to use the full consideration period at Employee’s option) solely to satisfy the requirements of the Older Workers Benefit Protection Act.  Any change(s) made to this Release by the parties during the consideration period will
              not restart the running of the consideration period.  Employer’s offer of the Separation Pay and Benefits will expire at the end of the consideration period set forth in the Separation Agreement if this Release has not been executed at such
              time.

          

    

    

    	

          	D.	
            Revocation Right.  For a period of seven (7) calendar days following Employee’s execution of this Release, Employee may revoke Employee’s agreement to those provisions of this Release releasing and
              waiving Employee’s rights and claims under the ADEA.  If Employee chooses to revoke the Release, Employee must deliver a written notice of revocation to Robert M. Jackson, Executive Vice President, General Counsel and Secretary at 2850 N.
              Harwood St. Suite 2200, Dallas, TX 75201, rjackson@cyrusone.com, with a copy to generalcounsel@cyrusone.com.  Any such revocation must be
              actually received by Employer within the Revocation Period or it will be null and void.  Because of Employee’s right to revoke Employee’s agreement to those provisions of this Release releasing and waiving Employee’s rights and claims under
              the ADEA, those provisions shall not become effective or enforceable until the revocation period has expired without Employee exercising the right to revoke.

          

    

    

    
      A-3

      
        

    

    
    

    

    

    

    	

          	E.	
            Effect of Revocation.  If Employee exercises Employee’s right to revoke Employee’s agreement to those provisions of this Release releasing and waiving Employee’s rights and claims under the ADEA or
              otherwise challenges this agreement under the OWBPA, the Separation Pay and Benefits shall be reduced to one thousand dollars ($1,000.00) in total and Employee shall not be entitled to the balance of the Separation Pay and Benefits as
              detailed in the Separation Agreement.  Employee acknowledges and agrees that the reduced Separation Pay and Benefits will constitute full and adequate consideration for Employee’s release of any and all non-ADEA claims in this Release as
              detailed in Section 1 above.

          

    

    

    	

          	F.	
            Effective Date.  With the exception of the provisions of this Release releasing and waiving Employee’s rights and claims under the ADEA, all other terms and conditions of this Release shall be
              binding and enforceable immediately upon Employee’s execution of this Release, and shall remain effective regardless of whether Employee revokes Employee’s agreement to those provisions of this Release releasing and waiving Employee’s rights
              and claims under the ADEA.

          

    

    

    	

          	G.	
            Preserved Rights of Employee.  This Release does not waive or release any rights or claims that Employee may have under the ADEA that arise after the execution of this Release.  In addition, this
              Release does not prohibit Employee from challenging the validity of this Release’s waiver and release of claims under the ADEA.

          

    

    

    

    

    
      A-4

      
        

    

    

    

    	4.	
            Consideration of Medicare’s Interests. Employee affirms, covenants, and warrants Employee is not a Medicare beneficiary and is not currently receiving, has not received in the past, will not have
              received at the time the Separation Pay and Benefits is due under the Separation Agreement, is not entitled to, is not eligible for, and has not applied for or sought Social Security Disability or Medicare benefits. In the event any statement
              in the preceding sentence is incorrect (for example, but not limited to, if Employee is a Medicare beneficiary, etc.), the following sentences of this paragraph apply. Employee affirms, covenants, and warrants Employee has made no claim for
              illness or injury against, nor is Employee aware of any facts supporting any claim against, the Released Parties under which the Released Parties could be liable for medical expenses incurred by Employee before or after the execution of this
              Release. Furthermore, Employee is aware of no medical expenses that Medicare has paid and for which the Released Parties are or could be liable now or in the future. Employee agrees and affirms that, to the best of Employee’s knowledge, no
              liens of any governmental entities, including those for Medicare conditional payments, exist. Employee will indemnify, defend, and hold the Released Parties harmless from Medicare claims, liens, damages, conditional payments, and rights to
              payment, if any, including attorneys’ fees, and Employee further agrees to waive any and all future private causes of action for damages pursuant to 42 U.S.C. § 1395y(b)(3)(A) et seq.

          

    

    

    

    

    
      	Accepted and Agreed to: 

            
	 
	 
	_____________________________________ 

            
	 
	 
	Dated: _______________________________, 2021  

            

    

    

    

    

  

  A-5Converted by EDGARwiz

NOTE AND WARRANT PURCHASE AGREEMENT

THIS NOTE AND WARRANT PURCHASE AGREEMENT (this “Agreement”) is entered into as of July 20, 2021 (the “Execution Date”), by and between Astro Aerospace, Ltd., a Nevada corporation (the “Company”) and Westworld Financial Capital LLC, a Colorado limited liability company (the “Investor”).

W I T N E S S E T H:

WHEREAS, the parties desire that, upon the terms and subject to the conditions contained herein, the Investor shall purchase from the Company and the Company shall issue and sell to the Investor, two senior secured promissory notes, the first one for Four Hundred Thousand (400,000) Dollars and the second for Eight Hundred and Fifty Thousand ($850,000) Dollars, for a total aggregate principal amount of One Million Two Hundred and Fifty Thousand ($1,250,000.00) Dollars, in the form attached hereto as Exhibit A and Exhibit B (the “Notes”), provided, however, that Investor is only obligated to deliver the $850,000 for the second Note if and when the Initial Registration Statement (as defined in the Registration Rights Agreement) is declared effective covering the aggregate amount of the Registrable Securities and otherwise in accordance with the Transaction Documents, and

WHEREAS, as further inducement to enter into this Agreement, the Company shall issue to Investor a warrant to purchase shares of Company Common Stock as further described herein.

NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Investor hereby agree as follows:

ARTICLE 1

PURCHASE AND SALE OF NOTES

1.1

Issuance and Sale of Notes. Subject to the terms and conditions of this Agreement and the other Transaction Documents, the Company agrees to issue and sell to the Investor, and the Investor agrees to purchase, (i) at Closing (as defined below) a convertible promissory note in the form of Exhibit A hereto (the “Note”) in the principal amount of Four Hundred Thousand ($400,000.00) Dollars (the “Initial Purchase Price”), and (ii) on the Follow-On Closing (as defined below) a Note in the form of Exhibit B hereto (and together with the Note from the Closing, the “Notes”) and in the principal amount of Eight Hundred Fifty Thousand ($850,000.00) Dollars (the “Follow-On Purchase Price” and together with the Initial Purchase Price, the “Purchase Price”).

1.2  

Warrants.  In addition to the Notes, the Company shall issue to Investor (i) at Closing, a warrant to purchase Thirty-Four thousand (34,000) shares of Common Stock of the Company; and (ii) at the Follow-On Closing, a warrant to purchase Eighty-Six 

Thousand (86,000) shares of Common Stock of the Company, in each case at an exercise price of five ($5.00) Dollars per share.  Such warrants shall be in the form attached hereto as Exhibit C and Exhibit D (the “Warrants”).

1.3

Closings. 

(a)

The Closing shall be held at the offices of the Company, (or remotely via the exchange of documents and signatures), on or before July 30, 2021 (the “First Closing”). 

(b)

The Follow-On Closing shall occur within five (5) business days following the Initial Registration Statement (as defined in the Registration Rights Agreement) being filed by the Company for the total amount of Registrable Securities (as defined in the Registration Rights Agreement) and being declared effective by the SEC (the “Follow-On Closing” and together with the Closing, the “Closings”).

(c)

At each Closing, the Company shall deliver the applicable Note and the Warrant to the Investor against payment of the applicable Purchase Price to the Company. 

ARTICLE 2

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

The Company hereby represents and warrants to the Investor the following:

2.1

Subsidiaries.  The Company does not presently own or control, directly or indirectly, any interest in any other corporation, association, or other business entity. The Company is not a party to any joint venture, partnership, or similar arrangement. 

2.2

Organization, Good Standing, and Qualification.  The Company is a corporation duly organized, validly existing, and in good standing under the laws of the State of Nevada and has all requisite corporate power and authority to carry on its business as now conducted. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure so to qualify would have a Material Adverse Effect (as hereafter defined) on the Company’s business or properties. 

2.3

Due Authorization, Validly Issued, Etc.  All shares of common stock to be issued upon the conversion of each Note and the exercise of each Warrant will be (upon issuance in accordance with their terms), duly authorized, validly issued, fully paid, nonassessable and free of all preemptive rights with respect to the transactions contemplated by this Agreement, and based in part upon the representations of the Investor in this Agreement will be issued in compliance with all applicable securities laws, as presently in effect of the United States and each of the states whose securities laws govern the issuance of the Warrants and such common stock.

2

2.4

Authorization.  All corporate action on the part of the Company, its officers, directors, and shareholders necessary for the authorization, execution and delivery of the Transaction Documents, the performance of all obligations of the Company hereunder and thereunder and the authorization, issuance (or reservation for issuance) and delivery of each Note, the shares of Common Stock to be issued upon the conversion of such Note, and the shares of Common Stock to be issued upon exercise of each Warrant (collectively, the “Securities”), has been taken or will be taken prior to the Closing and the Follow-On Closing, and the Transaction Documents constitute valid and legally binding obligations of the Company, enforceable in accordance with their respective terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies, and (iii) to the extent the indemnification provisions contained in the Transaction Documents may be limited by applicable federal or state laws. 

2.5

Valid Issuance of the Notes and the Warrants. 

(a)

The Notes and the Warrants being purchased by the Investor hereunder, based in part upon the representations of the Investor in this Agreement, will be issued in compliance with all applicable federal and state securities laws.  

(b)

All outstanding shares of Common Stock of the Company are duly and validly authorized and issued, fully paid and nonassessable, and were issued in compliance with all applicable federal and state securities laws.

2.6

 Filings, Consents and Approvals.  The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents.

2.7

Litigation.  There is no action, suit, proceeding, claim or investigation pending or, to the knowledge of the Company, currently threatened against the Company which questions the validity of the Transaction Documents, or the right of the Company to enter into any of them, or to consummate the transactions contemplated hereby or thereby, or which might result, either individually or in the aggregate, in any material adverse changes in the assets, condition, affairs, or prospects of the Company, financially or otherwise, or any change in the current equity ownership of the Company, nor is the Company aware that there is any basis for the foregoing.  The foregoing includes, without limitation, actions, pending or threatened (or any basis therefor known to the Company), involving the prior employment of any of the Company’s employees, their use in connection with the Company’s business of any information or techniques allegedly proprietary to any of their former employers, or their obligations under any agreements with prior employers.  The Company is not a party or subject to the provisions of any order, writ, injunction, judgment, or decree of any court or government agency or 

3

instrumentality.  

2.8

Compliance with Other Instruments.  The Company is not in violation or default of any provisions of its Articles of Incorporation, as amended to date, or Bylaws or, to its knowledge, of any instrument, judgment, order, writ, decree, mortgage, indenture, lease, license or contract to which it is a party or by which it is bound or, to its knowledge, of any provision of federal, state, or local statute, rule, or regulation applicable to the Company, except as would not reasonably be expected, singly or in the aggregate, to have a material and adverse effect on the results, operations, properties, prospects or financial condition of the Company and its Subsidiaries taken as a whole (“Material Adverse Effect”). The execution, delivery, and performance of the Transaction Documents and the consummation of the transactions contemplated thereby will not, to the Company’s knowledge, result in any such violation or be in conflict with or constitute, with or without the passage of time and giving of notice, either a default under any such provision, instrument, judgment, order, writ, decree or contract, or an event which results in the creation of any lien, charge, or encumbrance upon any assets of the Company or the suspension, revocation, impairment, forfeiture, or nonrenewal of any material permit, license, authorization, or approval applicable to the Company, its business or operations, or any of its assets or properties, except as would not reasonably be expected, singly or in the aggregate, to have a Material Adverse Effect. 

2.9

Compliance with Laws.  The conduct of business by the Company as presently and proposed to be conducted is not subject to continuing oversight, supervision, regulation or examination by any governmental official or body of the United States or any other jurisdiction wherein the Company conducts or proposes to conduct such business, except such regulation as is applicable to commercial enterprises generally. The Company has not received any notice of any violation of or noncompliance with, any federal, state, local or foreign laws, ordinances, regulations and orders (including, without limitation, those relating to environmental protection, occupational safety and health, federal securities laws, equal employment opportunity, consumer protection, credit reporting, "truth-in-lending", and warranties and trade practices) applicable to its business, the violation of, or noncompliance with, which would have a materially adverse effect on either the Company's business or operations, and the Company knows of no facts or set of circumstances which would give rise to such a notice.   

2.10

Capitalization. As of the Execution Date, the authorized capital stock of the Company consists of (a) 250,000,000 shares of Common Stock, par value of $0.0001 per share, of which approximately13,848,380 shares of Common Stock are issued and outstanding, (b) 50,000,000 shares of Series A Preferred Stock, of 1,562,500 shares of Series A Preferred are issued and outstanding and (c) 10,000 shares of Series B Preferred, of which 10,000 shares of Series B Preferred Stock are issued and outstanding. The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock options under the Company’s stock option plans, the issuance of shares of Common Stock to employees pursuant to the Company’s employee stock purchase plans and pursuant to the 

4

conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale of the Securities, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents. The issuance and sale of the Securities will not obligate the Company to issue shares of Common Stock or other securities to any Person (other than the Investor) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders.

2.11 

Listing and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act, nor has the Company received any notification that the SEC is contemplating terminating such registration. The Company has not, in the twelve (12) months preceding the Execution Date, received notice from the Principal Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Principal Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements.

2.12 

SEC Documents; Disclosure. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the one (1) year preceding the Execution Date (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the “SEC Documents”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Documents prior to the expiration of any such extension. As of their respective dates, the SEC Documents complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and other federal laws, rules and regulations applicable to such SEC Documents, and none of the SEC Documents when filed contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The financial statements of the Company included in the SEC Documents comply as to form and 

5

substance in all material respects with applicable accounting requirements and the published rules and regulations of the SEC or other applicable rules and regulations with respect thereto. Such financial statements have been prepared in accordance with generally accepted accounting principles applied on a consistent basis during the periods involved (except (a) as may be otherwise indicated in such financial statements or the notes thereto or (b) in the case of unaudited interim statements, to the extent they may not include footnotes or may be condensed or summary statements) and fairly present in all material respects the financial position of the Company as of the dates thereof and the results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments). The Company maintains a system of internal accounting controls appropriate for its size. There is no transaction, arrangement, or other relationship between the Company and an unconsolidated or other off balance sheet entity that is not disclosed by the Company in its financial statements or otherwise that would be reasonably likely to have a Material Adverse Effect. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided the Investor or its agents or counsel with any information that it believes constitutes or might constitute material, non-public information. The Company understands and confirms that the Investor will rely on the foregoing representation in effecting transactions in securities of the Company.

2.13 

No Conflicts. The execution, delivery and performance of this Agreement and the other Transaction Documents by the Company, and the consummation by the Company of the transactions contemplated hereby and thereby, including, without limitation, the issuance of the shares issuable upon the conversion of each Note and the exercise of each Warrant, do not and will not: (a) result in a violation of the Company’s  or any Subsidiary’s certificate or articles of incorporation, by-laws or other organizational or charter documents, (b) conflict with, or constitute a material default (or an event that with notice or lapse of time or both would become a material default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture, instrument or any “lock-up” or similar provision of any underwriting or similar agreement to which the Company or any Subsidiary is a party, or (c) result in a violation of any federal, state or local law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations) applicable to the Company or any Subsidiary or by which any property or asset of the Company or any Subsidiary is bound or affected (except for such conflicts, defaults, terminations, amendments, accelerations, cancellations and violations as would not, individually or in the aggregate, have a Material Adverse Effect), nor is the Company otherwise in violation of, conflict with or in default under any of the foregoing. The business of the Company is not being conducted in violation of any law, ordinance or regulation of any governmental entity, except for possible violations that either singly or in the aggregate do not and will not have a Material Adverse Effect. The Company is not required under federal, state or local law, rule or regulation to obtain any consent, authorization or order of, or make any filing or registration with, any court or 

6

governmental agency in order for it to execute, deliver or perform any of its obligations under this Agreement or the other Transaction Documents (other than any SEC, FINRA or state securities filings that may be required to be made by the Company in connection with the issuance of the Notes or the Warrants or subsequent to any Closing or any registration statement that may be filed pursuant hereto); provided that, for purposes of the representation made in this sentence, the Company is assuming and relying upon the accuracy of the relevant representations and agreements of Investor herein.

2.14 

No Material Adverse Change. No event has occurred that would have a Material Adverse Effect on the Company or any Subsidiary that has not been disclosed in subsequent SEC filings.

2.15 

Registration Rights. No Person (other than the Investor) has any right to cause the Company to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.

2.16  

No General Solicitation; No Integrated Offering.  Neither the Company, any Subsidiary, nor any of their respective affiliates, nor any Person acting on their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D under the Securities Act) in connection with the offer or sale of the Securities.  Neither the Company, any Subsidiary, nor any of their respective affiliates, nor any Person acting on their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require registration of the offer and sale of any of the Securities under the Securities Act, whether through integration with prior offerings or otherwise, or cause this offering of the Securities to be integrated with prior offerings by the Company in a manner that would require stockholder approval pursuant to the rules of the Principal Market on which any of the securities of the Company are listed or designated.  The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Principal Market.

2.17  

Intellectual Property Rights.  The Company and each Subsidiary own or possess adequate rights or licenses to use all material trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, governmental authorizations, trade secrets and rights necessary to conduct their respective businesses as now conducted.  None of the Company’s, nor any Subsidiary’s material Intellectual Property has expired or terminated, or, by the terms and conditions thereof, could expire or terminate within two years from the date of this Agreement.  The Company does not have any knowledge of any infringement by the Company and/or any Subsidiary of any material Intellectual Property of others, or of any such development of similar or identical trade secrets or technical information by others, and there is no claim, action or proceeding being made or brought against, or to the Company’s knowledge, being threatened against, the Company and/or any Subsidiary regarding the infringement of any Intellectual Property, which could reasonably be expected to have a Material Adverse Effect.

7

2.18  Environmental Laws.  To the Company’s knowledge, the Company and each Subsidiary (i) is in compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”), (ii) has received all permits, licenses or other approvals required of it under applicable Environmental Laws to conduct its respective businesses and (iii) is in compliance with all terms and conditions of any such permit, license or approval, except where, in each of the three foregoing clauses, the failure to so comply could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

2.19  

Title.  Except as disclosed in the SEC Documents, the Company and each Subsidiary has good and marketable title in fee simple to all real property owned by it and good and marketable title in all personal property owned by it that is material to the business of the Company and each Subsidiary, in each case free and clear of all Liens and, except for Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company or any Subsidiary and Liens for the payment of federal, state or other taxes, the payment of which is neither delinquent nor subject to penalties.  Any real property and facilities held under lease by the Company or any Subsidiary is held under valid, subsisting and enforceable leases with which the Company is in compliance with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company or any Subsidiary.

2.20 

Insurance. The Company and each Subsidiary is insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company and each Subsidiary is engaged.  Neither the Company, nor any Subsidiary has been refused any insurance coverage sought or applied for, and the Company has no reason to believe that it or any Subsidiary will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not materially and adversely affect the condition, financial or otherwise, or the earnings, business or operations of the Company, taken as a whole.

2.21 

Regulatory Permits. The Company and each Subsidiary possesses all material certificates, authorizations and permits issued by the appropriate federal, state or foreign regulatory authorities necessary to conduct its businesses, and neither the Company, nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit.

2.22  

Tax Status.  The Company and each Subsidiary has made or filed all federal and state income and all other material tax returns, reports and declarations required by any jurisdiction to which it is subject (unless and only to the extent that the Company has set aside on its books provisions reasonably adequate for the payment of all unpaid and unreported taxes) and has paid all taxes and other governmental assessments 

8

and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except those being contested in good faith and has set aside on its books provision reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply.  There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any such claim.

2.23 

Transactions With Affiliates.  Except as set forth in the SEC Documents, none of the officers or directors of the Company or any Subsidiary, and to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner, in each case in excess of the lesser of (i) $100,000 or (ii) one percent of the average of the Company’s total assets at year end for the last two completed fiscal years, other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company or any Subsidiary and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company.

2.24 

Application of Takeover Protections.  The Company and its board of directors have taken or will take prior to the Execution Date all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the articles of incorporation or the laws of the state of its incorporation which is or could become applicable to the Investor as a result of the transactions contemplated by this Agreement, including, without limitation, the Company’s issuance of the Securities and the Investor’s ownership of the Securities.

2.25  

Foreign Corrupt Practice.  Neither the Company, any Subsidiary, nor to the knowledge of the Company, any agent or other Person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any Person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended.

2.26 

Sarbanes-Oxley.  The Company is in compliance with all provisions of the Sarbanes-Oxley Act of 2002, as amended, which are applicable to it.

9

2.27 

Certain Fees.  No brokerage or finder’s fees or commissions are or will be payable by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents.  The Investor shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.

2.28 

Investment Company. The Company is not an “investment company” within the meaning of the Investment Company Act of 1940, as amended.

2.29 

Accountants. The Company’s accountants are set forth in the SEC Documents and, to the knowledge of the Company, such accountants are an independent registered public accounting firm as required by the Securities Act.

2.30  

No Market Manipulation. Neither the Company, nor any Subsidiary has, and to its knowledge no Person acting on either of their behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company.

2.31 

No Disqualification Events. None of the Company, any Subsidiary, any of their predecessors, any affiliated issuer, any director, executive officer, other officer of the Company or any Subsidiary participating in the offering contemplated hereby, any beneficial owner of 20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an “Issuer Covered Person”) is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a “Disqualification Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3) under the Securities Act.  The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event.

2.32 

Money Laundering. The Company and each Subsidiary is in compliance with, and has not previously violated, the USA PATRIOT ACT of 2001 and all other applicable U.S. and non-U.S. anti-money laundering laws and regulations, including, but not limited to, the laws, regulations and Executive Orders and sanctions programs administered by the U.S. Office of Foreign Assets Control, including, but not limited, to (i) Executive Order 13224 of September 23, 2001 entitled, “Blocking Property and Prohibiting Transactions With Persons Who Commit, Threaten to Commit, or Support Terrorism” (66 Fed. Reg. 49079 (2001)); and (ii) any regulations contained in 31 CFR, Subtitle B, Chapter V.

10

2.33 

Illegal or Unauthorized Payments; Political Contributions. Neither the Company, nor any Subsidiary has, nor, to the best of the Company’s knowledge (after reasonable inquiry of its officers and directors), any of the officers, directors, employees, agents or other representatives of the Company, any Subsidiary or any other business entity or enterprise with which the Company is or has been affiliated or associated, has, directly or indirectly, made or authorized any payment, contribution or gift of money, property, or services, whether or not in contravention of applicable law, (a) as a kickback or bribe to any Person or (b) to any political organization, or the holder of or any aspirant to any elective or appointive public office except for personal political contributions not involving the direct or indirect use of funds of the Company.

2.34 

Shell Company Status. The Company is not currently an issuer identified in Rule 144(i)(1)(i) under the Securities Act, is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act, has filed all reports and other materials required to be filed by Section 13 or 15(d) of the Exchange Act, as applicable during the preceding 12 months, and, as of a date at least one year prior to the Execution Date, has filed current “Form 10 information” with the SEC (as defined in Rule 144(i)(3) of the Securities Act) reflecting its status as an entity that is no longer an issuer described in Rule 144(i)(1)(i) of the Securities Act.

 

2.35

No representation or warranty or other statement made by the Company in this Agreement or any of the other Transaction Documents, including a officer’s certificate or otherwise in connection with the contemplated transactions contains any untrue statement of material fact or omits to state a material fact necessary to make the statements in this Agreement and the other Transaction Documents, in light of the circumstances in which they were made, not misleading.

2.36  Sole Warranties.  Investor acknowledge that the representations and warranties made by the Company in Sections 2.1 through 2.35 above are the sole representations warranties made to the Investor by the Company.

ARTICLE 3

REPRESENTATIONS AND WARRANTIES OF THE INVESTOR

 The Investor hereby represents and warrants that:

3.1

Authorization.  The Transaction Documents constitute valid and legally binding obligations of the Investor enforceable in accordance with their terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors’ rights generally and (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.

3.2

Purchase Entirely for Own Account. Investor represents that it is acquiring (a) each Note and (b) each Warrant and equity securities issuable upon exercise of the Warrants (collectively, the “Securities”) solely for investment for Investor’s own account 

11

not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that Investor has no present intention of selling, granting any participation in, or otherwise distributing the same.  The acquisition by Investor of any of the Securities shall constitute confirmation of the representation by such Investor that such Investor does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer, pledge, hypothecate or grant participations to such person or to any third person, with respect to any of the Securities.

3.3

Disclosure of Information.  The Investor acknowledges that it has received all the information that it has requested relating to the Company and the purchase of the Notes.  The Investor further represents that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the Notes.  The foregoing, however, does not limit or modify the representations and warranties of the Company in Section 2 of this Agreement or the right of the Investor to rely thereon. 

3.4

No Legal Advice From the Company. The Investor acknowledges that it has had the opportunity to review this Agreement and the transactions contemplated by this Agreement with its own legal counsel and investment and tax advisors. Except with respect to the representations, warranties and covenants contained in this Agreement, the Investor is relying solely on such counsel and advisors and not on any statements or representations of the Company or any of its representatives or agents for legal, tax or investment advice with respect to this investment, the transactions contemplated by this Agreement or the securities laws of any jurisdiction.

3.5

Accredited Investor.  The Investor is an “accredited investor” within the meaning of Rule 501 of Regulation D of the Securities and Exchange Commission (the “SEC”), as presently in effect as more particularly specified in the Accredited Investor Certification that the Investor is delivering to the Company prior to the Closing.      

3.6

Restricted Securities.  Investor understands that each Note, the Warrants (and the equity securities issuable upon the conversion of such Note and the exercise of each Warrant) that it is purchasing are characterized as “restricted securities” under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering, and that under such laws and applicable regulations such securities may be resold without registration under the Act, only in certain limited circumstances.  In this connection, the Investor represents that it is familiar with SEC Rule 144, as presently in effect, and understands the resale limitations imposed thereby and by the Act. 

3.7

Not an Affiliate. To the Investor’s knowledge, the Investor is not an officer, director or “affiliate” (as such term is defined in Rule 405 of the Securities Act) of the Company.

3.8 

Organization and Standing. The Investor is an entity duly formed, validly existing and in good standing under the laws of the jurisdiction of its formation with full 

12

right, limited liability company power and authority to enter into and to consummate the transactions contemplated by this Agreement and the other Transaction Documents.

3.9

Absence of Conflicts. The execution and delivery of this Agreement and the other Transaction Documents, and the consummation of the transactions contemplated hereby and thereby and compliance with the requirements hereof and thereof, will not (a) violate any law, rule, regulation, order, writ, judgment, injunction, decree or award binding on the Investor, (b) violate any provision of any indenture, instrument or agreement to which the Investor is a party or is subject, or by which the Investor or any of its assets is bound, or conflict with or constitute a material default thereunder, (c) result in the creation or imposition of any lien pursuant to the terms of any such indenture, instrument or agreement, or constitute a breach of any fiduciary duty owed by the Investor to any third party, or (d) require the approval of any third-party (that has not been obtained) pursuant to any material contract, instrument, agreement, relationship or legal obligation to which the Investor is subject or to which any of its assets, operations or management may be subject.

3.10

Disclosure; Access to Information. The Investor had an opportunity to review copies of the SEC Documents filed on behalf of the Company and has had access to all publicly available information with respect to the Company; provided, however,

that the Investor makes no representation or warranty hereunder with respect to any SEC Document and is relying on the representations and warranties of the Company in Article IV with respect to the SEC Documents.

3.11

Manner of Sale. At no time was the Investor presented with or solicited by or through any leaflet, public promotional meeting, television advertisement or any other form of general solicitation or advertisement regarding the Securities.

3.12

Legends.  It is understood that the certificates evidencing the Notes (and the common stock issuable upon conversion thereof) may bear the following legends: 

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), AND ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AS SET FORTH IN THIS CERTIFICATE.  THE SECURITIES REPRESENTED HEREBY MAY NOT BE SOLD, TRANSFERRED, OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR AN OPINION OF COUNSEL, REASONABLY ACCEPTABLE TO COUNSEL FOR THE COMPANY, TO THE EFFECT THAT THE PROPOSED SALE, TRANSFER, OR DISPOSITION MAY BE EFFECTUATED WITHOUT REGISTRATION UNDER THE ACT.”

13

ARTICLE 4

CONDITIONS OF THE INVESTOR’S OBLIGATIONS AT CLOSING

The obligations of the Investor under subsection 1.1(a) of this Agreement are subject to the fulfillment on or before the Closing and the Follow-on Closing of each of the following conditions, the waiver of which shall not be effective against any Investor who does not consent thereto:

4.1

Representations and Warranties.  The representations and warranties of the Company contained in Section 2 hereof shall be true on and as of the Closing and the Follow-on Closing.

4.2

Performance.  The Company shall have performed and complied with all agreements, obligations, and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing and the Follow-on Closing. 

 

4.3

 Delivery of Notes and Warrants.  The Company shall have delivered the fully executed Notes and Warrants to the Investor.

4.4

Delivery of Registration Rights Agreement. The Company shall have delivered to the Investor the fully executed Registration Rights Agreement in the form attached hereto as Exhibit E.

4.5

Delivery of Security Agreement. The Company shall have delivered to the Investor the fully executed Security Agreement in the form attached hereto as Exhibit F.

4.6

No Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or adopted by any court or governmental authority of competent jurisdiction that prohibits or directly and materially adversely affects any of the transactions contemplated by the Transaction Documents, and no proceeding shall have been commenced that may have the effect of prohibiting or materially adversely affecting any of the transactions contemplated by the Transaction Documents.

4.7

No Adverse Changes. Since the date of filing of the Company’s most recent SEC Document, no event that had or is reasonably likely to have a Material Adverse Effect has occurred.

4.8

No Suspension of Trading in or Delisting of Common Stock. The trading of the Common Stock shall not have been suspended by the SEC, the Principal Market or FINRA, or otherwise halted for any reason, and the Common Stock shall have been approved for listing or quotation on and shall not have been delisted from the Principal Market. 

4.9

Officer’s Certificate. The Investor shall have received the Closing Certificate executed by an executive officer of the Company and to the effect that all the 

14

conditions to such Closing shall have been satisfied as of the date of that particular Closing in the form attached hereto as Exhibit G.

4.10

DWAC Eligible. The Common Stock is DWAC Eligible and not subject to a “DTC chill.”

4.11

SEC Documents. All reports, schedules, registrations, forms, statements, information and other documents required to have been filed by the Company with the SEC pursuant to the reporting requirements of the Exchange Act (other than Forms 8-K) shall have been filed with the SEC within the applicable time periods prescribed for such filings under the Exchange Act.

4.12

No Violation. No statute, regulation, order, guidance, decree, writ, ruling or injunction shall have been enacted, entered, promulgated, threatened or endorsed by any federal, state, local or foreign court or governmental authority of competent jurisdiction, including, without limitation, the SEC, which prohibits the consummation of or which would materially modify or delay any of the transactions contemplated by the Transaction Documents.

ARTICLE 5

CONDITIONS OF THE COMPANY OBLIGATIONS AT CLOSING

The obligations of the Company to the Investor under this Agreement are subject to the fulfillment on or before the Closing and the Follow-on Closing of each of the following conditions by the Investor:

5.1

Representations and Warranties.  The representations and warranties of the Investor contained in Section 3 shall be true on and as of each Closing with the same effect as though such representations and warranties had been made on and as of such Closing. 

5.2

Payment of Purchase Price. The Investor shall have delivered the applicable Purchase Price in good funds.

ARTICLE 6

COVENANTS OF THE COMPANY 

6.1

Other Investments. Until the earlier of the repayment or conversion of each Note, the Company shall not, directly or indirectly, without Investor’s prior written consent, issue any securities that are convertible into any class of the Issuer’s equity securities. The Company covenants and agrees that it will not, without the prior written consent of the Investor, enter into any other equity line of credit agreement with any other party, without the Investor’s prior written consent, which consent may be granted or withheld in the Investor’s sole and absolute discretion. 

15

6.2

Filing of Current Report. The Company agrees that it shall file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto, with the SEC within the time required by the Exchange Act, relating to the transactions contemplated by, and describing the material terms and conditions of, the Transaction Documents (the “Current Report”). The Company shall permit the Investor to review and comment upon the final pre-filing draft version of the Current Report at least two (2) Trading Days prior to its filing with the SEC, and the Company shall give reasonable consideration to all such comments. The Investor shall use its reasonable best efforts to comment upon the final pre-filing draft version of the Current Report within one (1) Trading Day from the date the Investor receives it from the Company. 

6.3

Due Diligence; Confidentiality; Non-Public Information. The Investor shall have the right, from time to time as the Investor may reasonably deem appropriate, to perform reasonable due diligence on the Company during normal business hours.  The Company, each Subsidiary and their respective officers and employees shall provide information and reasonably cooperate with the Investor in connection with any reasonable request by the Investor related to the Investor’s due diligence of the Company. The Company agrees not to disclose any Confidential Information of the Investor to any third party, except for attorneys, accountants, advisors who have a need to know such Confidential Information and are bound by confidentiality, and shall not use any Confidential Information for any purpose other than in connection with, or in furtherance of, the transactions contemplated hereby.  The Company acknowledges that the Confidential Information of the Investor shall remain the property of the Investor and agrees that it shall take all reasonable measures to protect the secrecy of any Confidential Information disclosed by the Investor. The Company confirms that neither it nor any other Person acting on its behalf shall provide the Investor or its agents or counsel with any information that constitutes or might constitute material, non-public information, unless a simultaneous public announcement thereof is made by the Company in the manner contemplated by Regulation FD. In the event of a breach of the foregoing covenant by the Company or any Person acting on its behalf (as determined in the reasonable good faith judgment of the Investor), in addition to any other remedy provided herein or in the other Transaction Documents, the Investor shall have the right to make a public disclosure, in the form of a press release, public advertisement or otherwise, of such material, non-public information without the prior approval by the Company; provided the Investor shall have first provided notice to the Company that it believes it has received information that constitutes material, non-public information, and the Company shall have had at least twenty-four (24) hours to publicly disclose such material, non-public information prior to any such disclosure by the Investor, and the Company shall have failed to publicly disclose such material, non-public information within such time period. The Investor shall not have any liability to the Company, any Subsidiary, or any of their respective directors, officers, employees, stockholders, affiliates or agents, for any such disclosure. The Company understands and confirms that the Investor shall be relying on the foregoing covenants in effecting transactions in securities of the Company.

16

6.4

Taxes.  The Company shall pay any and all transfer, stamp or similar taxes that may be payable with respect to the issuance and delivery of any shares of Common Stock to the Investor made under this Agreement.

6.5

Transaction Documents. On the Execution Date, the Company shall deliver to the Investor executed copies of all of the Transaction Documents. 

ARTICLE 7

NOTICES; INDEMNIFICATION

7.1

Notices. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (a) personally served, (b) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (c) delivered by reputable air courier service with charges prepaid, or (d) transmitted by hand delivery, telegram, or e-mail as a PDF, addressed as set forth below or to such other address as such party shall have specified most recently by written notice given in accordance herewith. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (i) upon hand delivery or delivery by e-mail at the address designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (ii) on the second business day following the date of mailing by express courier service or on the fifth business day after deposited in the mail, in each case, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur.

The addresses for such communications shall be: 

If to the Company:

Astro Aerospace, Ltd. 

320 W. Main Street

Lewisville, TX 75057

Email: patricia@7mbholdings.com

Attention: Patricia Trompeter, CEO

If to the Investor: 

Westworld Financial Capital LLC 

900 Pearl Street   Suite 200 

Boulder, CO 80302

Email: 

Attention: 

with a copy to (that shall not constitute notice)

Diamond Law, Professional Corporation

17

Email: dan@diamondlawcorp.com

Either party hereto may from time to time change its address or e-mail for notices under this Section by giving at least one (1) days’ prior written notice of such changed address to the other party hereto.

7.2

Indemnification. Each party hereto (an “Indemnifying Party”) agrees to indemnify and hold harmless the other party along with its officers, directors, employees, and authorized agents and representatives, and each Person or entity, if any, who controls such party within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act or the rules and regulations thereunder (an “Indemnified Party”) from and against any and all Damages, joint or several, and any and all actions in respect thereof to which the Indemnified Party becomes subject to, resulting from, arising out of or relating to (i) any misrepresentation, breach of warranty or nonfulfillment of or failure to perform any covenant or agreement on the part of the Indemnifying Party contained in this Agreement, (ii) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, any registration statement pursuant to the Registration Rights Agreement or any post-effective amendment thereof or supplement thereto, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading, (iii) any untrue statement or alleged untrue statement of a material fact contained in any preliminary prospectus or contained in the final prospectus (as amended or supplemented, if the Company files any amendment thereof or supplement thereto with the SEC) or the omission or alleged omission to state therein any material fact necessary to make the statements made therein, in the light of the circumstances under which the statements therein were made, not misleading, or (iv) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation under the Securities Act, the Exchange Act or any state securities law, as such Damages are incurred, except to the extent such Damages result primarily from the Indemnified Party’s failure to perform any covenant or agreement contained in this Agreement or the Indemnified Party’s negligence, recklessness, fraud, willful misconduct or bad faith in performing its obligations under this Agreement; provided, however, that the foregoing indemnity agreement shall not apply to any Damages of an Indemnified Party to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made by an Indemnifying Party in reliance upon and in conformity with written information furnished to the Indemnifying Party by the Indemnified Party expressly for use in the Registration Statement, any post-effective amendment thereof or supplement thereto, or any preliminary prospectus or final prospectus (as amended or supplemented).

7.3

Method of Asserting Indemnification Claims. All claims for indemnification by any Indemnified Party under this Article 7 shall be asserted and resolved as follows:

(a)

In the event any claim or demand in respect of which an Indemnified Party might seek indemnity under the Section is asserted against or sought to be collected from 

18

such Indemnified Party by a Person other than a party hereto or an affiliate thereof (a “Third Party Claim”), the Indemnified Party shall deliver a written notification, enclosing a copy of all papers served, if any, and specifying the nature of and basis for such Third Party Claim and for the Indemnified Party’s claim for indemnification that is being asserted under any provision of 0 against an Indemnifying Party, together with the amount or, if not then reasonably ascertainable, the estimated amount, determined in good faith, of such Third Party Claim (a “Claim Notice”) with reasonable promptness to the Indemnifying Party. If the Indemnified Party fails to provide the Claim Notice with reasonable promptness after the Indemnified Party receives notice of such Third Party Claim, the Indemnifying Party shall not be obligated to indemnify the Indemnified Party with respect to such Third Party Claim to the extent that the Indemnifying Party’s ability to defend has been prejudiced by such failure of the Indemnified Party. The Indemnifying Party shall notify the Indemnified Party as soon as practicable within the period ending thirty (30) calendar days following receipt by the Indemnifying Party of either a Claim Notice or an Indemnity Notice (as defined below) (the “Dispute Period”) whether the Indemnifying Party disputes its liability or the amount of its liability to the Indemnified Party under 0 and whether the Indemnifying Party desires, at its sole cost and expense, to defend the Indemnified Party against such Third Party Claim.

(i)

If the Indemnifying Party notifies the Indemnified Party within the Dispute Period that the Indemnifying Party desires to defend the Indemnified Party with respect to the Third Party Claim pursuant to this Section 7, then the Indemnifying Party shall have the right to defend, with counsel reasonably satisfactory to the Indemnified Party, at the sole cost and expense of the Indemnifying Party, such Third Party Claim by all appropriate proceedings, which proceedings shall be vigorously and diligently prosecuted by the Indemnifying Party to a final conclusion or will be settled at the discretion of the Indemnifying Party (but only with the consent of the Indemnified Party in the case of any settlement that provides for any relief other than the payment of monetary damages or that provides for the payment of monetary damages as to which the Indemnified Party shall not be indemnified in full pursuant to this Section 7). The Indemnifying Party shall have full control of such defense and proceedings, including any compromise or settlement thereof; provided, however, that the Indemnified Party may, at the sole cost and expense of the Indemnified Party, at any time prior to the Indemnifying Party’s delivery of the notice referred to in the first sentence of this clause (i), file any motion, answer or other pleadings or take any other action that the Indemnified Party reasonably believes to be necessary or appropriate to protect its interests; and provided, further, that if requested by the Indemnifying Party, the Indemnified Party will, at the sole cost and expense of the Indemnifying Party, provide reasonable cooperation to the Indemnifying Party in contesting any Third Party Claim that the Indemnifying Party elects to contest. The Indemnified Party may participate in, but not control, any defense or settlement of any Third Party Claim controlled by the Indemnifying Party pursuant to this clause (i), and except as provided in the preceding sentence, the Indemnified Party shall bear its own costs and expenses with respect to such participation. Notwithstanding the foregoing, the Indemnified Party may takeover the control of the defense or settlement of a Third Party Claim at any time if it irrevocably waives its right to indemnity under the Section with respect to such Third Party Claim.

19

(ii)

If the Indemnifying Party fails to notify the Indemnified Party within the Dispute Period that the Indemnifying Party desires to defend the Third Party Claim pursuant to this Section, or if the Indemnifying Party gives such notice but fails to prosecute vigorously and diligently or settle the Third Party Claim, or if the Indemnifying Party fails to give any notice whatsoever within the Dispute Period, then the Indemnified Party shall have the right to defend, at the sole cost and expense of the Indemnifying Party, the Third Party Claim by all appropriate proceedings, which proceedings shall be prosecuted by the Indemnified Party in a reasonable manner and in good faith or will be settled at the discretion of the Indemnified Party(with the consent of the Indemnifying Party, which consent will not be unreasonably withheld). The Indemnified Party will have full control of such defense and proceedings, including any compromise or settlement thereof; provided, however, that if requested by the Indemnified Party, the Indemnifying Party will, at the sole cost and expense of the Indemnifying Party, provide reasonable cooperation to the Indemnified Party and its counsel in contesting any Third Party Claim which the Indemnified Party is contesting. Notwithstanding the foregoing provisions of this clause (ii), if the Indemnifying Party has notified the Indemnified Party within the Dispute Period that the Indemnifying Party disputes its liability or the amount of its liability hereunder to the Indemnified Party with respect to such Third Party Claim and if such dispute is resolved in favor of the Indemnifying Party in the manner provided in clause (c) below, the Indemnifying Party will not be required to bear the costs and expenses of the Indemnified Party’s defense pursuant to this clause (ii) or of the Indemnifying Party’s participation therein at the Indemnified Party’s request, and the Indemnified Party shall reimburse the Indemnifying Party in full for all reasonable costs and expenses incurred by the Indemnifying Party in connection with such litigation. The Indemnifying Party may participate in, but not control, any defense or settlement controlled by the Indemnified Party pursuant to this clause, and the Indemnifying Party shall bear its own costs and expenses with respect to such participation.

(iii) If the Indemnifying Party notifies the Indemnified Party that it does not dispute its liability or the amount of its liability to the Indemnified Party with respect to the Third Party Claim or fails to notify the Indemnified Party within the Dispute Period whether the Indemnifying Party disputes its liability or the amount of its liability to the Indemnified Party with respect to such Third Party Claim, the amount of Damages specified in the Claim Notice shall be conclusively deemed a liability of the Indemnifying Party and the Indemnifying Party shall pay the amount of such Damages to the Indemnified Party on demand. If the Indemnifying Party has timely disputed its liability or the amount of its liability with respect to such Third Party Claim, the Indemnifying Party and the Indemnified Party shall proceed in good faith to negotiate a resolution of such dispute; provided, however, that if the dispute is not resolved within thirty (30) days after the Claim Notice, the Indemnifying Party shall be entitled to institute such legal action as it deems appropriate.

(b)

In the event any Indemnified Party should have a claim against the Indemnifying Party that does not involve a Third Party Claim, the Indemnified Party shall deliver a written notification of a claim for indemnity specifying the nature of and basis for such claim, together with the amount or, if not then reasonably ascertainable, the estimated amount, determined in good faith, of such claim (an “Indemnity Notice”) with 

20

reasonable promptness to the Indemnifying Party. The failure by any Indemnified Party to give the Indemnity Notice shall not impair such party’s rights hereunder except to the extent that the Indemnifying Party demonstrates that it has been irreparably prejudiced thereby. If the Indemnifying Party notifies the Indemnified Party that it does not dispute the claim or the amount of the claim described in such Indemnity Notice or fails to notify the Indemnified Party within the Dispute Period whether the Indemnifying Party disputes the claim or the amount of the claim described in such Indemnity Notice, the amount of Damages specified in the Indemnity Notice will be conclusively deemed a liability of the Indemnifying Party and the Indemnifying Party shall pay the amount of such Damages to the Indemnified Party on demand. If the Indemnifying Party has timely disputed its liability or the amount of its liability with respect to such claim, the Indemnifying Party and the Indemnified Party shall proceed in good faith to negotiate a resolution of such dispute; provided, however, that if the dispute is not resolved within thirty (30) days after the Claim Notice, the Indemnifying Party shall be entitled to institute such legal action as it deems appropriate.

(c)

The Indemnifying Party agrees to pay the Indemnified Party, promptly as such expenses are incurred and are due and payable, for any reasonable legal fees or other reasonable expenses incurred by them in connection with investigating or defending any such Claim.

(d)

The indemnity provisions contained herein shall be in addition to (i) any cause of action or similar rights of the Indemnified Party against the Indemnifying Party or others, and (ii) any liabilities the Indemnifying Party may be subject to.

ARTICLE 8

Miscellaneous

8.1

Survival of Warranties.  All of the representations and warranties made herein shall survive the execution and delivery of this Agreement for a period of one year.  The Investor is entitled to rely, and the parties hereby acknowledge that the Investor has so relied, upon the truth, accuracy and completeness of each of the representations and warranties of the Company contained herein, irrespective of any independent investigation made by Investor.  The Company is entitled to rely, and the parties hereby acknowledge that the Company has so relied, upon the truth, accuracy and completeness of each of the representations and warranties of the Investor contained herein, irrespective of any independent investigation made by the Company.  

8.2

Successors and Assigns.  Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any Notes or Warrants sold hereunder or any Common Stock issued upon conversion thereof).  Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

21

8.3

Governing Law and Arbitration.  This Agreement shall be governed by and construed under the laws of the State of New York as applied to agreements among New York residents entered into and to be performed entirely within New York.  Any disputes, claims, or controversies arising out of or relating to the Transaction Documents, or the transactions, contemplated thereby, or the breach, termination, enforcement, interpretation or validity thereof, including the determination of the scope or applicability of this Agreement to arbitrate, shall be referred to and resolved solely and exclusively by binding arbitration to be conducted before the Judicial Arbitration and Mediation Service (“JAMS”), or its successor pursuant the expedited procedures set forth in the JAMS Comprehensive Arbitration Rules and Procedures (the “Rules” ), including Rules 16.1 and 16.2 of those Rules. The arbitration shall be held in New York, New York, before a tribunal consisting of three (3) arbitrators each of whom will be selected in accordance with the “strike and rank” methodology set forth in Rule 15. Either party to this Agreement may, without waiving any remedy under this Agreement, seek from any federal or state court sitting in the State of New York any interim or provisional relief that is necessary to protect the rights or property of that party, pending the establishment of the arbitral tribunal. The costs and expenses of such arbitration shall be paid by and be the sole responsibility of the Company, including but not limited to the Investor’s attorneys’ fees and each arbitrator’s fees. The arbitrators’ decision must set forth a reasoned basis for any award of damages or finding of liability. The arbitrators’ decision and award will be made and delivered as soon as reasonably possibly and in any case within sixty (60) days’ following the conclusion of the arbitration hearing and shall be final and binding on the parties and may be entered by any court having jurisdiction thereof.

8.4

Counterparts.  This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may also be executed via facsimile or by e-mail delivery of a “.pdf” format data file, either of which shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) this Agreement with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.

8.5

Titles and Subtitles.  The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 

8.6

Transaction Expenses; Enforcement of Transaction Documents.  The Company and each Investor shall pay their respective costs and expenses incurred with respect to the negotiation, execution, delivery and performance of this Agreement; provided that the Company will pay Investor’s legal fees in connection with the Transaction Documents in an amount not to exceed $25,000.

8.7

Amendments and Waivers.  This Agreement may not be amended or terminated and the observance of any term of this Agreement may not be waived other than in a written instrument signed by the party against whom enforcement of such 

22

waiver is sought. No failure or delay in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privilege.

8.8

Severability.  If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of this Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. 

8.9

Entire Agreement.  This Agreement and the documents referred to herein constitute the entire agreement among the parties and no party shall be liable or bound to any other party in any manner by any warranties, representations, or covenants except as specifically set forth herein or therein. 

8.10

Publicity. The Company and the Investor shall consult with each other in issuing any press releases or otherwise making public statements with respect to the transactions contemplated hereby and no party shall issue any such press release or otherwise make any such public statement, other than as required by law, without the prior written consent of the other parties, which consent shall not be unreasonably withheld or delayed, except that no prior consent shall be required if such disclosure is required by law, in which such case the disclosing party shall provide the other party with prior notice of such public statement. Notwithstanding the foregoing, the Company shall not publicly disclose the name of the Investor without the prior written consent of the Investor, except to the extent required by law. The Investor acknowledges that this Agreement and all or part of the Transaction Documents may be deemed to be “material contracts,” as that term is defined by Item 601(b)(10) of Regulation S-K, and that the Company may therefore be required to file such documents as exhibits to reports or registration statements filed under the Securities Act or the Exchange Act. The Investor further agrees that the status of such documents and materials as material contracts shall be determined solely by the Company, in consultation with its counsel.

8.11

Definitions.

“Agreement” shall have the meaning specified in the preamble hereof.

 “Bankruptcy Law” means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors.

“Closing Date” shall mean the date of the Closing and the date of the Follow-On Closing, as applicable, hereunder.

 “Common Stock” shall mean the Company’s common stock, $0.0001 par value per share, and any shares of any other class of common stock whether now or hereafter authorized, having the right to participate in the distribution of dividends (as and when declared) and assets (upon liquidation of the Company).

23

“Common Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 “Confidential Information” means any information disclosed by either party to this Agreement, or their affiliates, agents or representatives,  to the other party to this Agreement, either directly or indirectly, in writing, orally or by inspection of tangible objects (including, without limitation, documents, formulae, business information, trade secrets, technology, strategies. prototypes, samples, plant and equipment), which may or may not be designated as “Confidential,” “Proprietary” or some similar designation.  Information communicated orally shall be considered Confidential Information if such information is confirmed in writing as being Confidential Information within ten (10) Trading Days after the initial disclosure. Confidential Information may also include information disclosed by third parties.  Confidential Information shall not, however, include any information which (i) was publicly known and made generally available in the public domain prior to the time of disclosure by the disclosing party; (ii) becomes publicly known and made generally available after disclosure by the disclosing party to the receiving party through no fault, action or inaction of the receiving party; (iii) is already in the possession of the receiving party at the time of disclosure by the disclosing party as shown by the receiving party’s files and records immediately prior to the time of disclosure; (iv) is obtained by the receiving party from a third party without a breach of such third party’s obligations of confidentiality; (v) is independently developed by the receiving party without use of or reference to the disclosing party’s Confidential Information, as shown by documents and other competent evidence in the receiving party’s possession; or (vi) is required by law to be disclosed by the receiving party, provided that the receiving party gives the disclosing party prompt written notice of such requirement prior to such disclosure and assistance in obtaining an order protecting the information from public disclosure.

 “Custodian” means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.

“Damages” shall mean any loss, claim, damage, liability, cost and expense (including, without limitation, reasonable attorneys’ fees and disbursements and costs and 

 “DTC” shall mean The Depository Trust Company, or any successor performing substantially the same function for the Company.

“DTC/FAST Program” shall mean the DTC’s Fast Automated Securities Transfer Program.

“DWAC” shall mean Deposit Withdrawal at Custodian as defined by the DTC.

“DWAC Eligible” shall mean that (a) the Common Stock is eligible at DTC for full services pursuant to DTC’s operational arrangements, including, without limitation, 

24

transfer through DTC’s DWAC system, (b) the Company has been approved (without revocation) by the DTC’s underwriting department, (c) the Transfer Agent is approved as an agent in the DTC/FAST Program, (d) the shares of Common Stock issuable upon the conversion of each Note and the exercise of each Warrant, as applicable, are otherwise eligible for delivery via DWAC, and (e) the Transfer Agent does not have a policy prohibiting or limiting delivery of the Shares via DWAC.

“DWAC Shares” means shares of Common Stock that are (i) issued in electronic form, (ii) freely tradable and transferable and without restriction on resale and (iii) timely credited by the Company to the Investor’s or its designee’s specified DWAC account with DTC under the DTC/FAST Program, or any similar program hereafter adopted by DTC performing substantially the same function.

 “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 “Execution Date” shall have the meaning set forth in the preamble to this Agreement.

“FINRA” shall mean the Financial Industry Regulatory Authority, Inc.

 “Intellectual Property” shall mean all trademarks, trademark applications, trade names, service marks, service mark registrations, service names, patents, patent applications, patent rights, copyrights, inventions, licenses, approvals, government authorizations, trade secrets or other intellectual property rights.

 “Lien” means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or any other restriction.

 “Material Adverse Effect” shall mean any effect on the business, operations, properties, or financial condition of the Company and/or the Subsidiaries that is material and adverse to the Company and/or the Subsidiaries and/or any condition, circumstance, or situation that would prohibit or otherwise materially interfere with the ability of the Company and/or the Subsidiaries to enter into and/or perform its obligations under any Transaction Document.

 “Person” shall mean an individual, a corporation, a partnership, an association, a trust or other entity or organization, including a government or political subdivision or an agency or instrumentality thereof.

“Principal Market” shall mean any of the national exchanges (i.e. NYSE, NYSE AMEX, NASDAQ), or principal quotation systems (i.e. OTCQX, OTCQB, OTC Pink, the OTC Bulletin Board), or other principal exchange or recognized quotation system which is at the time the principal trading platform or market for the Common Stock.

 “Regulation D” shall mean Regulation D promulgated under the Securities Act.

25

 “Rule 144” shall mean Rule 144 promulgated under the Securities Act or any similar provision then in force under the Securities Act.

“SEC” shall mean the United States Securities and Exchange Commission. 

“Securities Act” shall mean the Securities Act of 1933, as amended.

“Short Sales” shall mean all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act.

“Subsidiary” or “Subsidiaries” means any Person the Company wholly-owns or controls, or in which the Company, directly or indirectly, owns a majority of the voting stock or similar voting interest, in each case that would be disclosable pursuant to Item 601(b)(21) of Regulation S-K promulgated under the Securities Act.

 “Trading Day” shall mean a day on which the Principal Market shall be open for business.

“Transaction Documents” shall mean this Agreement, the Registration Rights Agreement, the Security Agreement and all schedules and exhibits hereto and thereto, including, without limitation, the Warrants.

“Transfer Agent” shall mean Action Stock Transfer LTD, the current transfer agent of the Company, and any successor transfer agent of the Company.

[Signatures on page following]

26

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed by their respective officers thereunto duly authorized as of the Execution Date.

ASTRO AEROSPACE, LTD.

By: /s/Patricia Trompeter

Name: 

Patricia Trompeter

Title: 

Chief Executive Officer

WESTWORLD FINANCIAL CAPITAL LLC

By: /s/Christian Girodet

Name: Christian Girodet

Title: Director

27

EXHIBIT A 

FORM OF NOTE DELIVERED AT CLOSING

28

EXHIBIT B 

FORM OF NOTE DELIVERED AT FOLLOW-ON CLOSING

29

EXHBIT C

FORM OF WARRANT DELIVERED AT CLOSING

30

EXHIBIT D

FORM OF WARRANT DELIVERED AT FOLLOW-ON CLOSING

31

EXHIBIT E

REGISTRATION RIGHTS AGREEMENT

32

EXHIBIT F

SECURITY AGREEMENT

33

EXHIBIT G

CLOSING CERTIFICATE

34

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]